Critical Reviews in Oncogenesis最新文献_第5页

T cell receptor-engaging monoclonal antibodies mobilize the anti-tumor functions of invariant natural killer T cells T细胞受体单克隆抗体调动不变性自然杀伤T细胞的抗肿瘤功能

Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/critrevoncog.2023049947

Rupali Das

{"title":"T cell receptor-engaging monoclonal antibodies mobilize the anti-tumor functions of invariant natural killer T cells","authors":"Rupali Das","doi":"10.1615/critrevoncog.2023049947","DOIUrl":"https://doi.org/10.1615/critrevoncog.2023049947","url":null,"abstract":"Invariant natural killer T cells (iNKTs) are innate-type T lymphocytes that directly kill tumor cells or tumor-growth promoting immunosuppressive cells such as the tumor-associated macrophages. Additionally, iNKTs robustly transactivate the antitumor functions of T, B, natural killer, and dendritic cells as well as reinvigorate exhausted immune cells in the tumor microenvironment. As such, iNKTs make excellent candidates for inclusion in anti-cancer cellular therapies. However, to capitalize on the potential benefits of iNKT cell-based approaches, it is imperative that we develop new and clinically viable strategies to enhance their antitumor function. To that end, two novel monoclonal antibodies (mAbs) that selectively bind to the human (NKTT320) or murine (NKT14m) invariant T cell receptor have been recently developed and characterized. Studies using purified human iNKTs (in vitro) and a model of non-human primate (in vivo) reveal that NKTT320 promotes swift, vigorous and sustained iNKT cell activation that is accompanied by robust production of inflammatory mediators and bystander immune cell activation. Furthermore, NKTT320 augments expression of cytotoxic markers and human iNKT cell degranulation. Similarly, NKT14m prompts dramatic murine iNKT cell activation and functional response both in vitro and in vivo. However, antitumor efficacy of a single dose of NKT14m injection in tumor-bearing mice is limited and tumor-model dependent. In contrast, combination treatment of NKT14m with either low dose interleukin (IL)-12 or the chemotherapeutic agent, cyclophosphamide results in a superior antitumor response in vivo. This is evident by activation of both iNKTs and other immune cells, prolonged survival of the tumor-challenged mice and long-lasting immunity. Collectively, these recent studies justify further development of anti-iTCR mAbs that can be used alone or in conjunction with immunomodulatory agents to enhance iNKT cell antitumor immunity against various cancers.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135755304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Chemical Biology of NO that Regulates Oncogenic Signaling and Metabolism: NOS2 and Its Role in Inflammatory Disease. 调节致癌信号和代谢的NO的化学生物学：NOS2及其在炎症性疾病中的作用。

Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/CritRevOncog.2023047302

Katrina M Miranda, Lisa A Ridnour, Robert Y S Cheng, David A Wink, Douglas D Thomas

引用次数: 0

Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer. 二酸二氮鎓研究五十年：向拉里·K·基弗博士致敬。

Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/CritRevOncog.2023048491

Khosrow Kashfi

引用次数: 0

Preface. 前言

Critical Reviews in Oncogenesis Pub Date : 2023-01-01 DOI: 10.1615/CritRevOncog.v28.i1.60

Khosrow Kashfi

引用次数: 0

Preface 前言

Critical Reviews in Oncogenesis Pub Date : 2022-12-16 DOI: 10.1109/ASE.2006.54

Benjamin Bonavida

引用次数: 0

Improving Radiotherapy Response in the Treatment of Head and Neck Cancer. 改善头颈癌治疗中的放疗反应。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022044635

Christina A Wicker, Taylor Petery, Poornima Dubey, Trisha M Wise-Draper, Vinita Takiar

引用次数: 0

Role of the Tumor Microenvironment and the Influence of Epigenetics on the Tumor Microenvironment in Oral Carcinogenesis: Potential Implications. 肿瘤微环境在口腔癌变中的作用及表观遗传学对肿瘤微环境的影响:潜在意义。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022047088

Sagar Dholariya, Ragini D Singh, Madhuri Radadiya, Deepak Parchwani, Gaurav Sharma, Rashid Mir

引用次数: 0

Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer. 基因组改变指导转移性前列腺癌的治疗选择。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043298

Amy Davies, Arun A Azad, Edmond M Kwan

{"title":"Genomic Alterations to Guide Treatment Selection in Metastatic Prostate Cancer.","authors":"Amy Davies, Arun A Azad, Edmond M Kwan","doi":"10.1615/CritRevOncog.2022043298","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043298","url":null,"abstract":"Treatment options for men with metastatic prostate cancer have greatly expanded in the last decade. Androgen receptor pathway inhibitors, taxane cytotoxic therapy, poly(ADP-ribose) polymerase inhibitors, and radionuclide theranostics against prostate-specific membrane antigen have collectively contributed to incremental improvements in both quality and longevity of life for patients with metastatic castration-resistant prostate cancer (mCRPC). Despite these successes, few studies inform on optimal therapy selection and sequencing across this crowded treatment landscape. Genomic analysis of both tissue and liquid biopsy specimens shows promise in bridging this practice gap, with alterations in several key prostate cancer driver genes demonstrating clear associations with clinical outcomes, as well as informing use of novel precision medicine targeted therapies. In this review, we evaluate the current evidence of genomic alterations in various oncogenic signaling pathways as clinical biomarkers in mCRPC, focusing on correlative studies that analyzed outcomes based on findings in plasma cell-free DNA. We highlight the pitfalls of interpreting genomic findings in samples with substandard tumor content, and suggest pathologic and disease factors to consider when embarking upon tumor genotyping to guide treatment decisions in metastatic prostate cancer. As access to life-prolonging therapies improves, and barriers to cost-effective genotyping and reliable data interpretation are overcome, we anticipate that predictive and prognostic biomarkers that inform on disease biology, drug sensitivity, and therapy resistance will inevitably be integrated into the routine care of patients with metastatic prostate cancer.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation. 基于尺寸的循环无细胞DNA分析技术:局限性和临床应用。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043215

Thomas Pataillot-Meakin, Sylvain Ladame, Charlotte Bevan

{"title":"Technologies for Size-Based Analysis of Circulating Cell-Free DNA: Limitations and Clinical Implementation.","authors":"Thomas Pataillot-Meakin, Sylvain Ladame, Charlotte Bevan","doi":"10.1615/CritRevOncog.2022043215","DOIUrl":"https://doi.org/10.1615/CritRevOncog.2022043215","url":null,"abstract":"Prostate cancer is the second most common malignancy in men worldwide, and incidence is likely to rise in the next decade. The current screening options have limitations and have been shown to result in over-treatment of clinically insignificant disease. New biomarkers and technologies to detect them are therefore needed to better diagnose and stratify patients in primary care. Circulating cell-free DNA (ccfDNA) has gained interest as a potential minimally invasive biomarker, detectable in many bodily fluids (such as blood, urine, and cerebral spinal fluid) and reflecting the mutational landscape in tumors. More recently, the size distribution of ccfDNA fragments has also gained interest as a specific biomarker, where differences in size distribution have been observed between healthy volunteers and cancer patients, resulting in the new field of fragmentomics. Analysis of ccfDNA sizes provides avenues for alternative analytical technologies but commercial options are currently limited. Most focus on mutation detection and are subject to several biases that may affect size distribution. Here, we discuss the available technologies and identify major issues and considerations that may affect their implementation as a clinically useful test based on ccfDNA size profiling.","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40417038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer. BRCA2 的改变是前列腺癌治疗反应的决定因素。

Critical Reviews in Oncogenesis Pub Date : 2022-01-01 DOI: 10.1615/CritRevOncog.2022043233

Mia Hofstad, Emily Y Huang, Andrea Woods, Yi Yin, Neil B Desai, Ganesh V Raj

引用次数: 0